Ferric Ammonium Citrate is a pharmaceutical salt formed by ionic pairing of the active pharmacophore with a carefully selected counter-ion to optimise aqueous solubility, crystallinity, dissolution rate, and solid-state stability relative to the parent free form. Salt selection is a pivotal pharmaceutical development decision influencing polymorphic landscape, hygroscopicity, powder flow, compressibility, and bioavailability. Characterisation of Ferric Ammonium Citrate by XRPD, DSC, TGA, and dynamic vapour sorption is essential to define the approved solid-state form and ensure consistent quality across manufacturing batches.
The OEB assigned to Ferric Ammonium Citrate in pharmaceutical manufacturing is determined by structured potency banding based on its pharmacological target, NOAEL from repeat-dose studies, genotoxic classification under ICH M7, and reproductive toxicant status.
